Navigation Links
PharmAthene Announces Updated Time for Conference Call to Review BARDA rPA Decision
Date:12/8/2009

ANNAPOLIS, Md., Dec. 8 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP) a biodefense company specializing in the development and commercialization of medical countermeasures against chemical and biological threats, announced today that it will hold a conference call at 9:00 a.m. Eastern Time, on Wednesday, December 9, 2009 to provide an update on its recombinant protective antigen (rPA) anthrax vaccine program. The dial-in number for U.S. callers is 866-383-8108 and for international callers is 617-597-5343. The participant passcode is 50815141.

A replay of the conference call will be available beginning at approximately 1:00 p.m. Eastern Time on December 9, 2009 until approximately 11:59 p.m. Eastern Time January 9, 2010. The dial-in number from within the United States is 888-286-8010. For international callers, the dial-in number is 617-801-6888. The participant passcode is 67021476.

The webcast of the conference call will be available until January 9, 2010 and can be accessed from the company's website at http://www.pharmathene.com. A link to the webcast may be found on the Investor Relations section of the website.

About PharmAthene, Inc.

PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:

  • SparVax(TM) -- a second generation recombinant protective antigen (rPA) anthrax vaccine
  • Third generation rPA anthrax vaccine
  • Valortim®-- a fully human monoclonal antibody for the prevention and treatment of anthrax infection
  • Protexia® -- a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents
  • RypVax(TM) -- a recombinant dual antigen vaccine for plague

For more information about PharmAthene, please visit www.PharmAthene.com.

SOURCE PharmAthene, Inc.


'/>"/>
SOURCE PharmAthene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. PharmAthene Reports Third Quarter 2009 Financial and Operational Results
2. PharmAthene Executives Featured in Anthrax Pathogen Training Video for U.S. Department of Homeland Security
3. PharmAthene Presents Data for Valortim(R) Anthrax Anti-Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus - ACT 2009 Conference
4. PharmAthene to Present at the Rodman and Renshaw Annual Global Investment Conference September 10, 2009
5. PharmAthene Reports Second Quarter 2009 Financial and Operational Results
6. PharmAthene to Host Second Quarter 2009 Conference Call and Webcast on Thursday, August 13, 2009
7. PharmAthene, Inc. Closes on $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants
8. PharmAthenes 2nd Generation rPA Anthrax Vaccine, SparVax(TM), Completes FDA Regulatory Strategy Review
9. PharmAthene Reports First Quarter 2009 Financial and Operational Results
10. PharmAthene Announces New Date for First Quarter 2009 Conference Call and Webcast
11. PharmAthene to Host First Quarter 2009 Conference Call and Webcast on Thursday, May 14, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2016)... ... June 22, 2016 , ... Quantitative ... business incubator and current participant in the Phase 1 Ventures program, is leveraging ... , Quantitative Radiology Solutions helps physicians make better treatment decisions by quantifying ...
(Date:6/22/2016)... (PRWEB) , ... June 21, 2016 , ... New light-based ... cutting into the tissue — promise to enable both compact, wearable devices for point-of-care ... even deeper under the skin. , Recent work and visionary future directions are detailed ...
(Date:6/22/2016)... SAN DIEGO , June 22, 2016 /PRNewswire/ ... that has developed a testing platform designed specifically ... the formation of their scientific advisory board (SAB). ... of directors, the SAB is chartered to advise ... infectious disease assay platform. Led by Dr. ...
(Date:6/22/2016)... June 22, 2016 On Tuesday, June ... 4,843.76, up 0.14%; the Dow Jones Industrial Average advanced 0.14% ... 2,088.90, up 0.27%. The gains were broad based as five ... has initiated coverage on the following equities: Minerva Neurosciences Inc. ... PTLA ), Trevena Inc. (NASDAQ: TRVN ), ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
(Date:4/19/2016)... 2016 The new GEZE SecuLogic ... web-based "all-in-one" system solution for all door components. It ... the door interface with integration authorization management system, and ... The minimal dimensions of the access control and the ... installations offer considerable freedom of design with regard to ...
(Date:4/14/2016)... BioCatch ™, the global ... the appointment of Eyal Goldwerger as CEO. ... Goldwerger,s leadership appointment comes at a time of significant ... of its platform at several of the world,s largest ... unique cognitive and physiological factors, is a winner of ...
Breaking Biology News(10 mins):